BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Oncogene

• Publication date

  2008-08-07

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1038/onc.2008.109PMID 18408761PMCID PMC2748240
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant-dependent lung carcinomas.

  2007cited by this paper
• Pharmacology and Signaling Properties of Epidermal Growth Factor Receptor Isoforms Studied by Bioluminescence Resonance Energy Transfer

  2007cited by this paper
• Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors

  2007influential reference
• EGFR-T790M is a rare lung cancer susceptibility allele with enhanced kinase activity.

  2007cited by this paper
• Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy.

  2007cited by this paper
• Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib.

  2007cited by this paper
• MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

  2007influential reference
• The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies.

  2006cited by this paper
• Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272.

  2006cited by this paper
• HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors.

  2006influential reference
• Cancer Statistics, 2006

  2006cited by this paper
• Salvage Therapy in Patients with Advanced Non-small Cell Lung Cancer

  2006cited by this paper
• Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors

  2006cited by this paper
• High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer

  2006cited by this paper
• Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib

  2006cited by this paper
• Epidermal Growth Factor Receptor Activation in Glioblastoma through Novel Missense Mutations in the Extracellular Domain

  2006cited by this paper
• Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants

  2005influential reference
• EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

  2005cited by this paper
• Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology.

  2005cited by this paper
• Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

  2005cited by this paper
• ERBB Receptors and Cancer: The Complexity of Targeted Inhibitors

  2005cited by this paper
• Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression.

  2005cited by this paper
• ERBB receptors and cancer: the complexity of targeted inhibitors

  2005cited by this paper
• KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

  2005cited by this paper
• Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.

  2005cited by this paper
• An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor.

  2005cited by this paper
• Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.

  2005influential reference
• ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines.

  2005cited by this paper
• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  2004cited by this paper
• Athletics: Momentous sprint at the 2156 Olympics?

  2004cited by this paper
• Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase

  2004cited by this paper
• EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.

  2004influential reference
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

  2004influential reference
• Anticancer drugs: To the rescue?

  2004influential reference
• Inhibition of tumor growth by poly(ethylene glycol) derivatives of anti-ErbB2 antibodies

  2000cited by this paper
• Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts.

  1993cited by this paper
• Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene.

  1985cited by this paper
• Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells

  1984cited by this paper

• Epidermal growth factor receptor tyrosine kinase inhibitor for the treatment of non-small cell lung cancer in the past 30 years (1997-2026).

  2026cites this paper
• Exploiting intracellular oncogenic proteins to release cytotoxins

  2026cites this paper
• Discovery of novel pyridazinone derivatives as EGFRWT/ EGFRT790M kinase inhibitors; design, synthesis, antitumor evaluation, and molecular dynamic simulations.

  2026cites this paper
• Imidazole-[1,5‑a]‑Pyridines Can Occupy the EGFR Allostery with a Strong Polar Interaction.

  2026cites this paper
• In vitro metabolism studies of 5 acrylamide covalent drugs: Comparison with metabolism and disposition in human.

  2026cites this paper
• Relevance of EGFR-HER2 Dual Inhibition in Breast Cancer

  2026cites this paper
• Development of a Practical and Scalable Synthetic Route for DBPR112: A Clinical Candidate for the Treatment of Non-Small Cell Lung Cancer

  2026cites this paper
• Modular Vinyl Phosphonamidates for Cysteine-Directed Protein Targeting.

  2026cites this paper
• Case Report: A Bilateral Synchronous Primary Non‐Small Cell Lung Cancer Patient With Two Different EGFR Mutations

  2025cites this paper
• Steric disruption of EGFR oligomerization overcomes therapy resistance in non–small cell lung cancer

  2025cites this paper
• LZTR1 is a melanoma oncogene that promotes invasion and suppresses apoptosis

  2025cites this paper
• Tyrosine phosphoproteome profiling identifies cell-intrinsic signals limiting the efficacy of tyrosine kinase inhibitor therapies

  2025influential citation
• N-phenylquinazolin-4-amine-based EGFR TKIs suppress pulmonary fibrosis by modulating the EGFR/ERBB3 axis in epithelial–macrophage interaction

  2025cites this paper
• Unveiling the power of quinazoline derivatives: a new frontier in targeted cancer therapy.

  2025cites this paper
• Covalent Bifunctional Molecules (CBMs): Achievements and Challenges

  2025cites this paper
• Residue-Selective Inhibitors Discovery via Covalent DNA-Encoded Chemical Libraries with Diverse Warheads.

  2025cites this paper
• Exploring 4th Generation EGFR Inhibitors: A Review of Clinical Outcomes and Structural Binding Insights.

  2025cites this paper
• Updates on the treatment of epidermal growth factor receptor‐mutant non–small cell lung cancer

  2025cites this paper
• R2HaPpY: Rapid-robust phosphotyrosine peptide enrichment using HaloTag-Src SH2 pY superbinder

  2025cites this paper
• Diethenyl Sulfoximine (DESI) as an Irreversible Lysine-Targeting Warhead Enables the Design of Covalent Allosteric EGFR Inhibitor.

  2025cites this paper
• Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers.

  2025cites this paper
• Discovery of Carbodiimide Warheads to Selectively and Covalently Target Aspartic Acid in KRASG12D.

  2025cites this paper
• NRG1 fusion glycoproteins in cancer progression - Structural mechanisms and therapeutic potential: A review.

  2025cites this paper
• Molecular Crosstalk and Therapeutic Synergy: Tyrosine Kinase Inhibitors and Cannabidiol in Oral Cancer Treatment

  2025influential citation
• Afatinib for a non-small cell lung cancer patient in hemodialysis: A case report and literature review

  2025influential citation
• Chemical Adaptation in Drug Discovery: The Medicinal Chemistry Journey of Olverembatinib and Limertinib in Overcoming Kinase Drug Resistance.

  2025cites this paper
• Discovery of Potent and Selective Pyrrolo[2,3-d]pyrimidine Derivatives as Fourth-Generation EGFR Inhibitors Targeting Triple Mutations.

  2025cites this paper
• Study on Antitumor Secondary Metabolites from Euphorbia ebracteolata Hayata: Structural Characterization, Network Pharmacology, Molecular Docking and In Vitro

  2025cites this paper
• Type I RTKs: ErbB (epidermal growth factor) receptor family in GtoPdb v.2025.3

  2025cites this paper
• Novel Resistance Mechanisms to Second‐Generation EGFR Tyrosine Kinase Inhibitor Afatinib and Associations With Genomic Features in NSCLC

  2025cites this paper
• Relationship Between T790M Allele Frequency and Therapeutic Effects Before and After EGFR-TKI Administration Using Droplet Digital PCR in Non-small-cell Lung Cancer With EGFR Mutation

  2025cites this paper
• The peptide-Au clusters inhibit EGFR exon 19 deletion mutant non-small cell lung cancer

  2025cites this paper
• Design and Synthesis of Novel MEK Inhibitors for the Treatment of Solid Tumors

  2025cites this paper
• 6,7-Dimethoxy-2-methyl-4-substituted quinazolines: Design, synthesis, EGFR inhibitory activity, in vitro cytotoxicity, and in silico studies.

  2025cites this paper
• Effectiveness of afatinib after long-term gefitinib treatment for EGFR L858R and S768I compound mutation-positive lung adenocarcinoma: A case report

  2025cites this paper
• New alkanesulfonate-based quinazolinone-acetohydrazide scaffolds: Rational design, synthesis, molecular docking, anticancer properties and potential EGFR and its T790M/L858R mutants inhibitors.

  2025cites this paper
• Evolution of first versus next-line targeted therapies for metastatic non-small cell lung cancer.

  2025cites this paper
• Unleashing the Power of Covalent Drugs for Protein Degradation

  2025cites this paper
• Navigating First-Line Treatment Options for Patients With Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer.

  2025cites this paper
• EGFR amplification and PI3K pathway mutations identify a subset of breast cancers that synergistically respond to EGFR and PI3K inhibition

  2025cites this paper
• Preparation of ethynylsulfonamides and study of their reactivity with nucleophilic amino acids.

  2025cites this paper
• Specific detection of EGF-EGFR complexes on the cell surface and their dependency on EGFR-directed TKI treatment.

  2025cites this paper
• Synthesis of 4-tosyl quinazoline derivatives with the assistance of ultrasound irradiation as a guide to the reaction pathway

  2025cites this paper
• Modulating the phosphorylation status of target proteins through bifunctional molecules.

  2025cites this paper
• Jaceosidin overcomes osimertinib resistance in lung cancer by inducing G2/M cycle arrest through targeting DDB1.

  2025cites this paper
• Nanoparticle-Mediated Cosilencing of Drug Resistance and Compensatory Genes Enhances Lung Cancer Therapy.

  2025cites this paper
• Thermodynamics and mechanism of afatinib-EGFR binding through a QM/MM approach.

  2025cites this paper
• EGFR amplification and PI3K pathway mutations identify a subset of breast cancers that synergistically respond to EGFR and PI3K inhibition

  2025cites this paper
• A momentous progress update: epidermal growth factor receptor inhibitors as viable agents for combating cancer.

  2025cites this paper
• Osimertinib Induces Prolongation of Action Potential Duration via Downregulation of KCNN1 Expression: Exploring the Potential Mechanisms of Arrhythmia.

  2025cites this paper
• Selectively triggered: ROS-activated Michael acceptor prodrug strategy to enhance tumor targeting efficacy

  2025cites this paper
• WITHDRAWN: OncoStratifier: Stratifying Oncogene-addicted Cohorts By Drug Response

  2025cites this paper
• DeepEGFR a graph neural network for bioactivity classification of EGFR inhibitors

  2025cites this paper
• Recent Advances in the Development and Clinical Use of HER2 Inhibitors in Non-Small Cell Lung Cancer

  2025cites this paper
• Afatinib and Necitumumab in EGFR-Mutant NSCLC with Acquired Resistance to Tyrosine Kinase Inhibitors

  2024cites this paper
• Afatinib plus bevacizumab combination after osimertinib resistance in advanced EGFR-mutant non-small cell lung cancer: Phase II ABCD-study.

  2024cites this paper
• The Role of Tyrosine Kinases in Cancer: Signal Transduction Mechanisms and Therapeutic Targets

  2024cites this paper
• Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update

  2024cites this paper
• Recent advances in the design of small molecular drugs with acrylamides covalent warheads.

  2024cites this paper
• Evolving therapeutic landscape of EGFR-TKIs in NSCLC

  2024cites this paper
• Delineating cysteine-reactive compound modulation of cellular proteostasis processes

  2024cites this paper
• Targeted protein degradation: advances in drug discovery and clinical practice

  2024cites this paper
• Stimulation of neutral lipid synthesis via viral growth factor signaling and ATP citrate lyase during vaccinia virus infection

  2024cites this paper
• Fused in silico and bioactivity evaluation method for drug discovery: T001-10027877 was identified as an antiproliferative agent that targets EGFRT790M/C797S/L858R and EGFRT790M/L858R

  2024cites this paper
• Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies

  2024cites this paper
• Advancements in understanding cardiotoxicity of EGFR- TKIs in non-small cell lung cancer treatment and beyond

  2024cites this paper
• A Probe-Free Occupancy Assay to Assess a Targeted Covalent Inhibitor of Receptor Tyrosine-Protein Kinase erbB-2.

  2024cites this paper
• Targeting EGFR with molecular degraders as a promising strategy to overcome resistance to EGFR inhibitors.

  2024cites this paper
• Advanced technologies for screening and identifying covalent inhibitors

  2024cites this paper
• Advances in Small-Molecule Dual Inhibitors Targeting EGFR and HER2 Receptors as Anti-Cancer Agents.

  2024cites this paper
• Targeting the RAS upstream and downstream signaling pathway for Cancer treatment.

  2024cites this paper
• AFATINIB-A COMPREHENSIVE REVIEW OF ANALYTICAL METHODS DEVELOPED IN PHARMACEUTICALS AND BIOLOGICAL MATRICES

  2024cites this paper
• Management and Mechanisms of Diarrhea Induced by Tyrosine Kinase Inhibitors in Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer

  2024cites this paper
• Design, synthesis, and evaluation of antitumor activity of Mobocertinib derivatives, a third-generation EGFR inhibitor.

  2024cites this paper
• Detection of EGFR gene mutations for prescription of targeted drugs for non-small cell lung cancer

  2024cites this paper
• Discovery of novel pyrazole based Urea/Thiourea derivatives as multiple targeting VEGFR-2, EGFRWT, EGFRT790M tyrosine kinases and COX-2 Inhibitors, with anti-cancer and anti-inflammatory activities.

  2024cites this paper
• A heterogeneous pharmaco-transcriptomic landscape induced by targeting a single oncogenic kinase

  2024cites this paper
• Vinylpyridine as a Tunable Covalent Warhead Targeting C797 in EGFR.

  2024cites this paper
• EGFR degraders in non‐small‐cell lung cancer: Breakthrough and unresolved issue

  2024cites this paper
• Recent nanotechnological aspects and molecular targeting strategies for lung cancer therapy

  2024cites this paper
• Chemical Proteomics-Guided Discovery of Covalent Ligands for Cancer Proteins.

  2024cites this paper
• Covalent drug – An emerging framework for targeted drug development

  2024cites this paper
• Synthetic routes and clinical application of Small-Molecule HER2 inhibitors for cancer therapy.

  2024cites this paper
• 1,3,5-Triazine as a promising scaffold in the development of therapeutic agents against breast cancer.

  2024cites this paper
• FDA-approved small molecule kinase inhibitors for cancer treatment (2001-2015): Medical indication, structural optimization, and binding mode Part I.

  2024cites this paper
• Screening of protein-based inhibitors for the intracellular domain of epidermal growth factor receptor by directed evolution using the yeast Gγ recruitment system.

  2024cites this paper
• Synthetic Routes and Clinical Application of Representative Small-Molecule EGFR Inhibitors for Cancer Therapy

  2024cites this paper
• Thiophene-based N-phenyl pyrazolines: Synthesis, anticancer activity, molecular docking and ADME study

  2024cites this paper
• Targeting EGFR degradation by autophagosome degraders.

  2024cites this paper
• Bilateral keratitis associated with afatinib therapy

  2024cites this paper
• Evaluating protein cross-linking as a therapeutic strategy to stabilize SOD1 variants in a mouse model of familial ALS

  2024cites this paper
• Clinical phase II trial shows that combining osimertinib and afatinib resistance EGFR recurrent mutation in EGFR-mutant lung cancer

  2024cites this paper
• A phase I dose-escalation study of pulsatile afatinib in patients with recurrent or progressive brain cancer

  2024cites this paper
• Prolonged Response to Afatinib and Crizotinib in a Rare Case of EGFR-, HER2-, MET- and ROS1-Alterated Lung Adenocarcinoma

  2024cites this paper
• Covalent Epidermal Growth Factor Receptor (EGFR) Inhibitors in Targeted Therapy of Drug-Resistant Non-Small Cell Lung Cancer (A Review)

  2024cites this paper
• コバレントドラッグのための細胞内反応化学

  2024cites this paper
• Covalent Proximity Inducers

  2024cites this paper
• Green/red fluorescent protein disrupting drugs for real‐time permeability tracking in three‐dimensional tumor spheroids

  2024cites this paper
• Cereblon-Based Bifunctional Degrader of SOS1, BTX-6654, Targets Multiple KRAS Mutations and Inhibits Tumor Growth.

  2024cites this paper
• A split intein and split luciferase-coupled system for detecting protein-protein interactions

  2024influential citation